Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
30.26
+0.19 (0.63%)
Aug 4, 2025, 11:42 AM - Market open

Company Description

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.

Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical logo
CountryUnited States
Founded2002
IPO DateMay 7, 2015
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees357
CEOVikram Karnani

Contact Details

Address:
100 Technology Center Drive, Suite 300
Stoughton, Massachusetts 02072
United States
Phone781 713 3699
Websitecollegiumpharma.com

Stock Details

Ticker SymbolCOLL
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001267565
CUSIP Number19459J104
ISIN NumberUS19459J1043
SIC Code2834

Key Executives

NamePosition
Vikram KarnaniChief Executive Officer, President, Executive Vice President and Director
Colleen TupperExecutive Vice President and Chief Financial Officer
Scott DreyerExecutive Vice President and Chief Commercial Officer
Dr. Thomas B. Smith FAAFP, M.D.Executive Vice President and Chief Medical Officer
David DieterExecutive Vice President, General Counsel and Corporate Secretary
Jane GonnermanExecutive Vice President of Strategy and Corporate Development
Dean J. PatrasChief People Officer
Scott SudduthHead of Technical Operations

Latest SEC Filings

DateTypeTitle
Jul 9, 2025144Filing
Jul 8, 2025144Filing
Jul 7, 2025144Filing
Jul 7, 20258-KCurrent Report
Jul 2, 2025144Filing
Jul 2, 2025144Filing
Jun 9, 2025144Filing
Jun 6, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jun 6, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jun 6, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments